The HIF2α inhibitor belzutifan has shown promising activity in patients with tumours arising in the context of Von Hippel–Lindau disease (VHL), an autosomal-dominant cancer predisposition syndrome arising from the deletion or inactivation of…
The HIF2α inhibitor belzutifan has shown promising activity in patients with tumours arising in the context of Von Hippel–Lindau disease (VHL), an autosomal-dominant cancer predisposition syndrome arising from the deletion or inactivation of…